The DNA sequencing technology developer, which counts Nan Fung and Lam Research as investors, has added $60m to take its funding to $145m in the last 18 months.
Omniome, a US-based DNA sequencing platform developer backed by property developer Nan Fung and chipmaker Lam Research, has completed a $60m series C round led by private equity firm Madrone Capital Partners.
Founded in 2013, Omniome is developing a DNA sequencing platform it claims offers higher accuracy than comparable technologies. The company focuses on cancer diagnostics and single-cell sequencing, but also expects its platform to have broader applications.
The funding will be combined with an undisclosed amount of debt financing…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
